Loading…

Antibodies Against Phosphorylcholine Among 60-Year-Olds: Clinical Role and Simulated Interactions

Antibodies against phosphorylcholine (anti-PC) are implicated as protection markers in atherosclerosis, cardiovascular disease (CVD), and other chronic inflammatory conditions. Mostly, these studies have been focused on IgM. In this study, we determined IgG, IgG1, and IgG2 anti-PC among 60-year-olds...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in cardiovascular medicine 2022-04, Vol.9, p.809007-809007
Main Authors: Samal, Shailesh Kumar, Panda, Pritam Kumar, Vikström, Max, Leander, Karin, de Faire, Ulf, Ahuja, Rajeev, Frostegård, Johan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c537t-b0e7358bb8d0dedeed72bc9127a2abb6bf5e52c64b965d7c86f1359210eba6b63
cites cdi_FETCH-LOGICAL-c537t-b0e7358bb8d0dedeed72bc9127a2abb6bf5e52c64b965d7c86f1359210eba6b63
container_end_page 809007
container_issue
container_start_page 809007
container_title Frontiers in cardiovascular medicine
container_volume 9
creator Samal, Shailesh Kumar
Panda, Pritam Kumar
Vikström, Max
Leander, Karin
de Faire, Ulf
Ahuja, Rajeev
Frostegård, Johan
description Antibodies against phosphorylcholine (anti-PC) are implicated as protection markers in atherosclerosis, cardiovascular disease (CVD), and other chronic inflammatory conditions. Mostly, these studies have been focused on IgM. In this study, we determined IgG, IgG1, and IgG2 anti-PC among 60-year-olds. Based on a 7-year follow-up of 60-year-olds (2,039 men and 2,193 women) from Stockholm County, we performed a nested case-control study of 209 incident CVD cases with 620 age- and sex-matched controls. Anti-PC was determined using ELISA. We predicted the binding affinity of PC with our fully human, in-house-produced IgG1 anti-PC clones (i.e., A01, D05, and E01) using the molecular docking and molecular dynamics simulation approach, to retrieve information regarding binding properties to PC. After adjustment for confounders, IgG and IgG2 anti-PC showed some significant associations, but IgG1 anti-PC was much stronger as a protection marker. IgG1 anti-PC was associated with an increased risk of CVD below 33rd, 25th, and 10th percentile and of stroke below 33rd and 25th, and of myocardial infarction (MI) below 10th percentile. Among men, a strong association with stroke was determined below the 33rd percentile [HR 9.20, CI (2.22-38.12); = 0.0022]. D05 clone has higher binding affinity followed by E01 and A01 using molecular docking and further have been confirmed during the course of 100 ns simulation. The stability of the D05 clone with PC was substantially higher. IgG1 anti-PC was a stronger protection marker than IgG anti-PC and IgG2 anti-PC and also separately for men. The molecular modeling approach helps in identifying the intrinsic properties of anti-PC clones and atomistic interactions with PC.
doi_str_mv 10.3389/fcvm.2022.809007
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ef9ee30ea8cf4a91916abe66aa376db5</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_ef9ee30ea8cf4a91916abe66aa376db5</doaj_id><sourcerecordid>2656742679</sourcerecordid><originalsourceid>FETCH-LOGICAL-c537t-b0e7358bb8d0dedeed72bc9127a2abb6bf5e52c64b965d7c86f1359210eba6b63</originalsourceid><addsrcrecordid>eNp1kstv1DAQxiMEolXpnRPKkQNZHDt-cUBaLa-VKhXxEpwsPya7Lk68tZOi_vdkm6XqHvDFo5nv-80cvqJ4XqMFIUK-bu1Nt8AI44VAEiH-qDjFWPIKUfrz8YP6pDjP-QohVNNGUCaeFieENlxiIU4LvewHb6LzkMvlRvs-D-Xnbcy7bUy3wW5j8D2Uyy72m5Kh6hfoVF0Gl9-Uq2nirQ7llxig1L0rv_puDHoAV677AZK2g499flY8aXXIcH74z4rvH95_W32qLi4_rlfLi8pSwofKIOCECmOEQw4cgOPYWFljrrE2hpmWAsWWNUYy6rgVrK0JlbhGYDQzjJwV65nror5Su-Q7nW5V1F7dNWLaKJ0GbwMoaCUAQaCFbRsta1kzbYAxrQlnztCJVc2s_Ad2ozmiHVq_pwpUM90u0KR_9V_9O_9jebd9HFXDG1Hv8W9n-aTtwFnoh6TDket40vut2sQbJRGh05sALw-AFK9HyIPqfLYQgu4hjllhRhlvMONykqJZalPMOUF7v6ZGap8jtc-R2udIzTmaLC8enndv-Jca8heUA8fK</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2656742679</pqid></control><display><type>article</type><title>Antibodies Against Phosphorylcholine Among 60-Year-Olds: Clinical Role and Simulated Interactions</title><source>PubMed Central</source><creator>Samal, Shailesh Kumar ; Panda, Pritam Kumar ; Vikström, Max ; Leander, Karin ; de Faire, Ulf ; Ahuja, Rajeev ; Frostegård, Johan</creator><creatorcontrib>Samal, Shailesh Kumar ; Panda, Pritam Kumar ; Vikström, Max ; Leander, Karin ; de Faire, Ulf ; Ahuja, Rajeev ; Frostegård, Johan</creatorcontrib><description>Antibodies against phosphorylcholine (anti-PC) are implicated as protection markers in atherosclerosis, cardiovascular disease (CVD), and other chronic inflammatory conditions. Mostly, these studies have been focused on IgM. In this study, we determined IgG, IgG1, and IgG2 anti-PC among 60-year-olds. Based on a 7-year follow-up of 60-year-olds (2,039 men and 2,193 women) from Stockholm County, we performed a nested case-control study of 209 incident CVD cases with 620 age- and sex-matched controls. Anti-PC was determined using ELISA. We predicted the binding affinity of PC with our fully human, in-house-produced IgG1 anti-PC clones (i.e., A01, D05, and E01) using the molecular docking and molecular dynamics simulation approach, to retrieve information regarding binding properties to PC. After adjustment for confounders, IgG and IgG2 anti-PC showed some significant associations, but IgG1 anti-PC was much stronger as a protection marker. IgG1 anti-PC was associated with an increased risk of CVD below 33rd, 25th, and 10th percentile and of stroke below 33rd and 25th, and of myocardial infarction (MI) below 10th percentile. Among men, a strong association with stroke was determined below the 33rd percentile [HR 9.20, CI (2.22-38.12); = 0.0022]. D05 clone has higher binding affinity followed by E01 and A01 using molecular docking and further have been confirmed during the course of 100 ns simulation. The stability of the D05 clone with PC was substantially higher. IgG1 anti-PC was a stronger protection marker than IgG anti-PC and IgG2 anti-PC and also separately for men. The molecular modeling approach helps in identifying the intrinsic properties of anti-PC clones and atomistic interactions with PC.</description><identifier>ISSN: 2297-055X</identifier><identifier>EISSN: 2297-055X</identifier><identifier>DOI: 10.3389/fcvm.2022.809007</identifier><identifier>PMID: 35479288</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>antibodies ; Cardiovascular Medicine ; immune system ; molecular docking and dynamics ; myocardial infarction ; phosphorylcholine (PC) ; SAbPred ; stroke</subject><ispartof>Frontiers in cardiovascular medicine, 2022-04, Vol.9, p.809007-809007</ispartof><rights>Copyright © 2022 Samal, Panda, Vikström, Leander, de Faire, Ahuja and Frostegård.</rights><rights>Copyright © 2022 Samal, Panda, Vikström, Leander, de Faire, Ahuja and Frostegård. 2022 Samal, Panda, Vikström, Leander, de Faire, Ahuja and Frostegård</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c537t-b0e7358bb8d0dedeed72bc9127a2abb6bf5e52c64b965d7c86f1359210eba6b63</citedby><cites>FETCH-LOGICAL-c537t-b0e7358bb8d0dedeed72bc9127a2abb6bf5e52c64b965d7c86f1359210eba6b63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035555/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035555/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35479288$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-474815$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:149486518$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Samal, Shailesh Kumar</creatorcontrib><creatorcontrib>Panda, Pritam Kumar</creatorcontrib><creatorcontrib>Vikström, Max</creatorcontrib><creatorcontrib>Leander, Karin</creatorcontrib><creatorcontrib>de Faire, Ulf</creatorcontrib><creatorcontrib>Ahuja, Rajeev</creatorcontrib><creatorcontrib>Frostegård, Johan</creatorcontrib><title>Antibodies Against Phosphorylcholine Among 60-Year-Olds: Clinical Role and Simulated Interactions</title><title>Frontiers in cardiovascular medicine</title><addtitle>Front Cardiovasc Med</addtitle><description>Antibodies against phosphorylcholine (anti-PC) are implicated as protection markers in atherosclerosis, cardiovascular disease (CVD), and other chronic inflammatory conditions. Mostly, these studies have been focused on IgM. In this study, we determined IgG, IgG1, and IgG2 anti-PC among 60-year-olds. Based on a 7-year follow-up of 60-year-olds (2,039 men and 2,193 women) from Stockholm County, we performed a nested case-control study of 209 incident CVD cases with 620 age- and sex-matched controls. Anti-PC was determined using ELISA. We predicted the binding affinity of PC with our fully human, in-house-produced IgG1 anti-PC clones (i.e., A01, D05, and E01) using the molecular docking and molecular dynamics simulation approach, to retrieve information regarding binding properties to PC. After adjustment for confounders, IgG and IgG2 anti-PC showed some significant associations, but IgG1 anti-PC was much stronger as a protection marker. IgG1 anti-PC was associated with an increased risk of CVD below 33rd, 25th, and 10th percentile and of stroke below 33rd and 25th, and of myocardial infarction (MI) below 10th percentile. Among men, a strong association with stroke was determined below the 33rd percentile [HR 9.20, CI (2.22-38.12); = 0.0022]. D05 clone has higher binding affinity followed by E01 and A01 using molecular docking and further have been confirmed during the course of 100 ns simulation. The stability of the D05 clone with PC was substantially higher. IgG1 anti-PC was a stronger protection marker than IgG anti-PC and IgG2 anti-PC and also separately for men. The molecular modeling approach helps in identifying the intrinsic properties of anti-PC clones and atomistic interactions with PC.</description><subject>antibodies</subject><subject>Cardiovascular Medicine</subject><subject>immune system</subject><subject>molecular docking and dynamics</subject><subject>myocardial infarction</subject><subject>phosphorylcholine (PC)</subject><subject>SAbPred</subject><subject>stroke</subject><issn>2297-055X</issn><issn>2297-055X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNp1kstv1DAQxiMEolXpnRPKkQNZHDt-cUBaLa-VKhXxEpwsPya7Lk68tZOi_vdkm6XqHvDFo5nv-80cvqJ4XqMFIUK-bu1Nt8AI44VAEiH-qDjFWPIKUfrz8YP6pDjP-QohVNNGUCaeFieENlxiIU4LvewHb6LzkMvlRvs-D-Xnbcy7bUy3wW5j8D2Uyy72m5Kh6hfoVF0Gl9-Uq2nirQ7llxig1L0rv_puDHoAV677AZK2g499flY8aXXIcH74z4rvH95_W32qLi4_rlfLi8pSwofKIOCECmOEQw4cgOPYWFljrrE2hpmWAsWWNUYy6rgVrK0JlbhGYDQzjJwV65nror5Su-Q7nW5V1F7dNWLaKJ0GbwMoaCUAQaCFbRsta1kzbYAxrQlnztCJVc2s_Ad2ozmiHVq_pwpUM90u0KR_9V_9O_9jebd9HFXDG1Hv8W9n-aTtwFnoh6TDket40vut2sQbJRGh05sALw-AFK9HyIPqfLYQgu4hjllhRhlvMONykqJZalPMOUF7v6ZGap8jtc-R2udIzTmaLC8enndv-Jca8heUA8fK</recordid><startdate>20220411</startdate><enddate>20220411</enddate><creator>Samal, Shailesh Kumar</creator><creator>Panda, Pritam Kumar</creator><creator>Vikström, Max</creator><creator>Leander, Karin</creator><creator>de Faire, Ulf</creator><creator>Ahuja, Rajeev</creator><creator>Frostegård, Johan</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>ACNBI</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>DF2</scope><scope>ZZAVC</scope><scope>DOA</scope></search><sort><creationdate>20220411</creationdate><title>Antibodies Against Phosphorylcholine Among 60-Year-Olds: Clinical Role and Simulated Interactions</title><author>Samal, Shailesh Kumar ; Panda, Pritam Kumar ; Vikström, Max ; Leander, Karin ; de Faire, Ulf ; Ahuja, Rajeev ; Frostegård, Johan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c537t-b0e7358bb8d0dedeed72bc9127a2abb6bf5e52c64b965d7c86f1359210eba6b63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>antibodies</topic><topic>Cardiovascular Medicine</topic><topic>immune system</topic><topic>molecular docking and dynamics</topic><topic>myocardial infarction</topic><topic>phosphorylcholine (PC)</topic><topic>SAbPred</topic><topic>stroke</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Samal, Shailesh Kumar</creatorcontrib><creatorcontrib>Panda, Pritam Kumar</creatorcontrib><creatorcontrib>Vikström, Max</creatorcontrib><creatorcontrib>Leander, Karin</creatorcontrib><creatorcontrib>de Faire, Ulf</creatorcontrib><creatorcontrib>Ahuja, Rajeev</creatorcontrib><creatorcontrib>Frostegård, Johan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SWEPUB Uppsala universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Uppsala universitet</collection><collection>SwePub Articles full text</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in cardiovascular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Samal, Shailesh Kumar</au><au>Panda, Pritam Kumar</au><au>Vikström, Max</au><au>Leander, Karin</au><au>de Faire, Ulf</au><au>Ahuja, Rajeev</au><au>Frostegård, Johan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibodies Against Phosphorylcholine Among 60-Year-Olds: Clinical Role and Simulated Interactions</atitle><jtitle>Frontiers in cardiovascular medicine</jtitle><addtitle>Front Cardiovasc Med</addtitle><date>2022-04-11</date><risdate>2022</risdate><volume>9</volume><spage>809007</spage><epage>809007</epage><pages>809007-809007</pages><issn>2297-055X</issn><eissn>2297-055X</eissn><abstract>Antibodies against phosphorylcholine (anti-PC) are implicated as protection markers in atherosclerosis, cardiovascular disease (CVD), and other chronic inflammatory conditions. Mostly, these studies have been focused on IgM. In this study, we determined IgG, IgG1, and IgG2 anti-PC among 60-year-olds. Based on a 7-year follow-up of 60-year-olds (2,039 men and 2,193 women) from Stockholm County, we performed a nested case-control study of 209 incident CVD cases with 620 age- and sex-matched controls. Anti-PC was determined using ELISA. We predicted the binding affinity of PC with our fully human, in-house-produced IgG1 anti-PC clones (i.e., A01, D05, and E01) using the molecular docking and molecular dynamics simulation approach, to retrieve information regarding binding properties to PC. After adjustment for confounders, IgG and IgG2 anti-PC showed some significant associations, but IgG1 anti-PC was much stronger as a protection marker. IgG1 anti-PC was associated with an increased risk of CVD below 33rd, 25th, and 10th percentile and of stroke below 33rd and 25th, and of myocardial infarction (MI) below 10th percentile. Among men, a strong association with stroke was determined below the 33rd percentile [HR 9.20, CI (2.22-38.12); = 0.0022]. D05 clone has higher binding affinity followed by E01 and A01 using molecular docking and further have been confirmed during the course of 100 ns simulation. The stability of the D05 clone with PC was substantially higher. IgG1 anti-PC was a stronger protection marker than IgG anti-PC and IgG2 anti-PC and also separately for men. The molecular modeling approach helps in identifying the intrinsic properties of anti-PC clones and atomistic interactions with PC.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>35479288</pmid><doi>10.3389/fcvm.2022.809007</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2297-055X
ispartof Frontiers in cardiovascular medicine, 2022-04, Vol.9, p.809007-809007
issn 2297-055X
2297-055X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_ef9ee30ea8cf4a91916abe66aa376db5
source PubMed Central
subjects antibodies
Cardiovascular Medicine
immune system
molecular docking and dynamics
myocardial infarction
phosphorylcholine (PC)
SAbPred
stroke
title Antibodies Against Phosphorylcholine Among 60-Year-Olds: Clinical Role and Simulated Interactions
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T18%3A57%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibodies%20Against%20Phosphorylcholine%20Among%2060-Year-Olds:%20Clinical%20Role%20and%20Simulated%20Interactions&rft.jtitle=Frontiers%20in%20cardiovascular%20medicine&rft.au=Samal,%20Shailesh%20Kumar&rft.date=2022-04-11&rft.volume=9&rft.spage=809007&rft.epage=809007&rft.pages=809007-809007&rft.issn=2297-055X&rft.eissn=2297-055X&rft_id=info:doi/10.3389/fcvm.2022.809007&rft_dat=%3Cproquest_doaj_%3E2656742679%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c537t-b0e7358bb8d0dedeed72bc9127a2abb6bf5e52c64b965d7c86f1359210eba6b63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2656742679&rft_id=info:pmid/35479288&rfr_iscdi=true